New Quinoxaline Derivatives as Potential MT1 and MT2 Receptor Ligands

Ever since the idea arose that melatonin might promote sleep and resynchronize circadian rhythms, many research groups have centered their efforts on obtaining new melatonin receptor ligands whose pharmacophores include an aliphatic chain of variable length united to an N-alkylamide and a methoxy group (or a bioisostere), linked to a central ring. Substitution of the indole ring found in melatonin with a naphthalene or quinoline ring leads to compounds of similar affinity. The next step in this structural approximation is to introduce a quinoxaline ring (a bioisostere of the quinoline and naphthalene rings) as the central nucleus of future melatoninergic ligands.

[1]  J. Boutin,et al.  Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). , 2012, European journal of medicinal chemistry.

[2]  M. Mor,et al.  Melatonin Receptor Agonists: New Options for Insomnia and Depression Treatment , 2011, CNS neuroscience & therapeutics.

[3]  D. Caignard,et al.  Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands. , 2011, European journal of medicinal chemistry.

[4]  D. Cardinali,et al.  Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics? , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  J. Boutin,et al.  Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. , 2011, European journal of medicinal chemistry.

[6]  Masaharu Nakayama,et al.  1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists. , 2011, Journal of medicinal chemistry.

[7]  D. Hadjipavlou-Litina,et al.  Synthesis and Biological Evaluation of New Quinoxaline Derivatives as Antioxidant and Anti‐Inflammatory Agents , 2011, Chemical biology & drug design.

[8]  Y. Wong,et al.  Synthesis of Substituted N‐[3‐(3‐Methoxyphenyl)propyl] Amides as Highly Potent MT2‐Selective Melatonin Ligands. , 2010 .

[9]  Y. Wong,et al.  Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. , 2010, Bioorganic & medicinal chemistry letters.

[10]  R. Villar,et al.  New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. , 2010, Bioorganic & medicinal chemistry.

[11]  M. Can,et al.  A new donor–acceptor double-cable carbazole polymer with perylene bisimide pendant group: Synthesis, electrochemical, and photovoltaic properties , 2009 .

[12]  P. Witt-Enderby,et al.  Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands. , 2009, Bioorganic & medicinal chemistry.

[13]  D. Sugden,et al.  Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat , 2009, Neuroscience Letters.

[14]  J. Boutin,et al.  Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. , 2009, Bioorganic & Medicinal Chemistry.

[15]  J. Boutin,et al.  Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. , 2008, Bioorganic & medicinal chemistry.

[16]  G. Vergoten,et al.  Homology modeling of MT1 and MT2 receptors. , 2008, European journal of medicinal chemistry.

[17]  M. Mor,et al.  N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. , 2007, Journal of medicinal chemistry.

[18]  M. Dubocovich Melatonin receptors: role on sleep and circadian rhythm regulation. , 2007, Sleep medicine.

[19]  K. Gates,et al.  Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. , 2007, Journal of medicinal chemistry.

[20]  T. Roth,et al.  Insomnia: definition, prevalence, etiology, and consequences. , 2007, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[21]  A. Monge,et al.  Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity. , 2007, Bioorganic & medicinal chemistry.

[22]  G. Olayiwola,et al.  Synthesis and neuropharmacological activity of some quinoxalinone derivatives , 2007 .

[23]  J. Pintor,et al.  Melatonin receptors in the eye: location, second messengers and role in ocular physiology. , 2007, Pharmacology & therapeutics.

[24]  E. Urrestarazu,et al.  Clasificación de los trastornos del sueño , 2007 .

[25]  D. Cardinali,et al.  Role of the Melatonin System in the Control of Sleep , 2007, CNS drugs.

[26]  D. Zlotos Recent Advances in Melatonin Receptor Ligands , 2005, Archiv der Pharmazie.

[27]  D. Sugden,et al.  Binding affinity and biological activity of oxygen and sulfur isosteres at melatonin receptors as a function of their hydrogen bonding capability. , 2004, Bioorganic chemistry.

[28]  J. Boutin,et al.  New selective ligands of human cloned melatonin MT1 and MT2 receptors , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  J. Boutin,et al.  Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. , 2003, Bioorganic & Medicinal Chemistry.

[30]  M. Waring,et al.  2,3-Bifunctionalized Quinoxalines: Synthesis, DNA Interactions and Evaluation of Anticancer, Anti-tuberculosis and Antifungal Activity , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[31]  J. Nicolas,et al.  Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. , 2002, Journal of medicinal chemistry.

[32]  R. Nonno,et al.  Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. , 2001, Bioorganic & medicinal chemistry.

[33]  L Morin-Allory,et al.  Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors. , 1998, Journal of medicinal chemistry.

[34]  R. Nonno,et al.  Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. , 1998, Journal of medicinal chemistry.

[35]  M. Langlois,et al.  Recent developments in melatonin receptor ligands , 1997 .

[36]  P. Witt-Enderby,et al.  Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands , 1997 .

[37]  R. Nonno,et al.  1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues. , 1997, Journal of medicinal chemistry.

[38]  R. Nonno,et al.  Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. , 1997, Journal of medicinal chemistry.

[39]  M. Langlois,et al.  Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study. , 1997, Journal of medicinal chemistry.

[40]  J. Jansen,et al.  The high affinity melatonin binding site probed with conformationally restricted ligands--II. Homology modeling of the receptor. , 1996, Bioorganic & medicinal chemistry.

[41]  J. Jansen,et al.  The high affinity melationin binding site probed with conformationally restricted ligand--I. Pharmacophore and minireceptor models. , 1996, Bioorganic & medicinal chemistry.

[42]  A. Poso,et al.  A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. , 1996, European journal of pharmacology.

[43]  A. Tsotinis,et al.  Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. , 1996, Journal of medicinal chemistry.

[44]  A. López de Cerain,et al.  Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2. , 1995, Journal of medicinal chemistry.

[45]  P Delagrange,et al.  Design and synthesis of new naphthalenic derivatives as ligands for 2-[125I]iodomelatonin binding sites. , 1995, Journal of medicinal chemistry.

[46]  D. Lewis,et al.  Structural requirements at the melatonin receptor , 1995, British journal of pharmacology.

[47]  D. Sugden,et al.  Mapping the melatonin receptor. 1. the 5-methoxyl group of melatonin is not an essential requirement for biological activity , 1994 .

[48]  D. Lesieur,et al.  Novel naphthalenic ligands with high affinity for the melatonin receptor. , 1992, Journal of medicinal chemistry.

[49]  G. P. Ellis,et al.  Cyanation of aromatic halides , 1987 .

[50]  K. Hermann,et al.  Synthese Cyan‐substituierter Heterocyclen mit Tetraethyl‐ammoniumcyanid , 1981 .